Cytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy

Drug Profile

Cytosine deaminase herpes simplex virus-1/thymidine kinase fusion gene therapy

Alternative Names: Ad5-CD/TKrep; Ad5-yCD/mutTKSR39rep-ADP; Ad5-yCD/mutTKSR39rep-hIL12; Radiation-sensitising gene therapy - NewGenPharm/Henry Ford Health System; Theragene

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Henry Ford Health System
  • Developer Henry Ford Health System; NewGenPharm
  • Class Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Prostate cancer

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy) in USA (Intratumoural) (NCT03281382)
  • 01 Aug 2016 Seoul National University Hospital initiates enrolment in a phase trial for Pancreatic cancer (Combination therapy) in South Korea (Parenteral) (NCT02894944)
  • 26 Nov 2015 No recent reports on development identified - Phase-II for Prostate cancer in South Korea (Intraprostatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top